Share Price and Basic Stock Data
Last Updated: October 26, 2025, 9:02 am
| PEG Ratio | 1.07 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Kingfa Science & Technology (India) Ltd operates in the plastics industry, focusing on plastic and plastic products. For the fiscal year ending March 2025, the company reported sales of ₹1,745 Cr, reflecting a substantial increase from ₹1,404 Cr in the previous year. This growth trajectory is indicative of the company capitalizing on rising demand within the plastics sector, which is projected to grow as industries increasingly rely on innovative materials. Quarterly sales figures also highlight this trend, with the most recent quarter, June 2025, recording sales of ₹462 Cr, an increase from ₹404 Cr in March 2025. The company’s revenue from operations per share stood at ₹1,440.64, which is higher than typical sector averages, showcasing its operational efficiency. Kingfa’s ability to maintain a steady growth rate in a competitive market underlines its strategic positioning and operational capabilities.
Profitability and Efficiency Metrics
Kingfa Science & Technology has demonstrated strong profitability, with a reported net profit of ₹153 Cr for the fiscal year ending March 2025, up from ₹81 Cr in March 2023. This translates to a remarkable net profit margin of 8.76%, which is above many industry peers. The operating profit margin (OPM) stood at 13%, reflecting effective cost management strategies. In terms of efficiency, the return on equity (ROE) was an impressive 23.2%, while the return on capital employed (ROCE) was 30.6%, indicating the company’s ability to generate returns on investments efficiently. Furthermore, the interest coverage ratio (ICR) was reported at 35.23x, showcasing a robust capacity to meet interest obligations, which is significantly higher than typical sector benchmarks. This combination of high profitability and efficiency metrics suggests a well-managed company with strong financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Kingfa Science & Technology reflects a solid financial foundation, with total assets reported at ₹1,156 Cr as of March 2025, against total liabilities of ₹1,156 Cr, indicating a balanced approach to asset management. The company’s reserves have grown to ₹716 Cr, up from ₹576 Cr the previous year, demonstrating a commitment to reinvestment and financial stability. With borrowings reported at a mere ₹43 Cr, the total debt to equity ratio stands at 0.05, indicating a low reliance on debt financing. The current ratio of 2.02 and quick ratio of 1.31 further illustrate the company’s strong liquidity position. Additionally, the book value per share was ₹601.63, suggesting that the company has substantial net assets relative to its market capitalization of ₹6,401 Cr. This solid balance sheet positions Kingfa well for future growth and investment opportunities.
Shareholding Pattern and Investor Confidence
Kingfa Science & Technology’s shareholding pattern indicates a healthy distribution of equity, with promoters holding 67.02% of the shares as of March 2025. This level of promoter holding reflects strong insider confidence in the company’s prospects. Foreign institutional investors (FIIs) accounted for 7.78%, while domestic institutional investors (DIIs) held 8.75%, indicating a balanced interest from both foreign and domestic investors. The public shareholding stood at 16.45%, which is relatively stable. The number of shareholders has increased to 12,610, highlighting growing investor interest and confidence in the company’s performance. The rise in DII participation from negligible levels to 8.75% over recent quarters signifies an increasing institutional interest, which can enhance market perception and stability. Overall, the shareholding pattern suggests a well-rounded investor base, contributing positively to the company’s market reputation.
Outlook, Risks, and Final Insight
Looking ahead, Kingfa Science & Technology is well-positioned to leverage its operational strengths and market presence. However, potential risks include fluctuations in raw material prices and regulatory changes impacting the plastics industry. The company must navigate these challenges while maintaining its growth trajectory. A focus on innovation and sustainability could mitigate some risks associated with environmental regulations. If Kingfa continues to enhance its product offerings and operational efficiencies, it can expect sustained growth in revenue and profitability. Conversely, failure to adapt to market dynamics or manage costs effectively might hinder its performance. Thus, while the outlook remains positive, the company’s ability to manage external pressures will be crucial for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Kingfa Science & Technology (India) Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Mitsu Chem Plast Ltd | 135 Cr. | 99.7 | 138/83.2 | 18.1 | 71.4 | 0.20 % | 10.4 % | 8.17 % | 10.0 |
| IIRM Holdings India Ltd | 520 Cr. | 76.4 | 153/69.7 | 25.1 | 19.4 | 0.00 % | 23.5 % | 18.6 % | 5.00 |
| Fiberweb (India) Ltd | 127 Cr. | 44.0 | 66.0/34.0 | 7.37 | 61.2 | 0.00 % | 10.0 % | 8.88 % | 10.0 |
| Deep Polymers Ltd | 113 Cr. | 46.6 | 80.0/35.7 | 22.1 | 36.2 | 0.00 % | 8.22 % | 6.10 % | 10.0 |
| DDev Plastiks Industries Ltd | 3,219 Cr. | 311 | 360/213 | 16.5 | 80.7 | 0.56 % | 33.9 % | 24.9 % | 1.00 |
| Industry Average | 1,587.92 Cr | 506.31 | 47.93 | 157.76 | 0.27% | 16.30% | 12.17% | 8.25 |
All Competitor Stocks of Kingfa Science & Technology (India) Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 346 | 351 | 340 | 366 | 339 | 351 | 394 | 404 | 416 | 418 | 440 | 470 | 462 |
| Expenses | 338 | 317 | 310 | 311 | 289 | 306 | 356 | 354 | 359 | 362 | 389 | 409 | 404 |
| Operating Profit | 8 | 34 | 31 | 55 | 50 | 45 | 38 | 51 | 57 | 56 | 51 | 60 | 58 |
| OPM % | 2% | 10% | 9% | 15% | 15% | 13% | 10% | 13% | 14% | 13% | 12% | 13% | 13% |
| Other Income | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 2 | 1 | 5 | 2 | 4 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 3 | 30 | 27 | 49 | 47 | 40 | 32 | 45 | 52 | 50 | 49 | 54 | 54 |
| Tax % | 27% | 26% | 25% | 26% | 25% | 25% | 25% | 26% | 25% | 26% | 30% | 23% | 26% |
| Net Profit | 2 | 22 | 20 | 37 | 35 | 30 | 24 | 34 | 39 | 37 | 35 | 42 | 40 |
| EPS in Rs | 2.04 | 18.24 | 16.70 | 30.24 | 28.93 | 24.44 | 20.09 | 27.70 | 32.26 | 30.77 | 28.60 | 34.60 | 32.86 |
Last Updated: August 1, 2025, 6:20 pm
Below is a detailed analysis of the quarterly data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 462.00 Cr.. The value appears to be declining and may need further review. It has decreased from 470.00 Cr. (Mar 2025) to 462.00 Cr., marking a decrease of 8.00 Cr..
- For Expenses, as of Jun 2025, the value is 404.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 409.00 Cr. (Mar 2025) to 404.00 Cr., marking a decrease of 5.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 60.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 2.00 Cr..
- For OPM %, as of Jun 2025, the value is 13.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00%.
- For Other Income, as of Jun 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 54.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 54.00 Cr..
- For Tax %, as of Jun 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
- For Net Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 32.86. The value appears to be declining and may need further review. It has decreased from 34.60 (Mar 2025) to 32.86, marking a decrease of 1.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 178 | 219 | 314 | 427 | 602 | 702 | 742 | 627 | 1,048 | 1,404 | 1,488 | 1,745 | 1,790 |
| Expenses | 181 | 212 | 288 | 408 | 560 | 666 | 698 | 607 | 966 | 1,276 | 1,303 | 1,520 | 1,565 |
| Operating Profit | -3 | 6 | 27 | 19 | 41 | 35 | 43 | 20 | 82 | 128 | 185 | 225 | 226 |
| OPM % | -2% | 3% | 8% | 5% | 7% | 5% | 6% | 3% | 8% | 9% | 12% | 13% | 13% |
| Other Income | 0 | 0 | 1 | 4 | 6 | 4 | 3 | 6 | -22 | 2 | 3 | 9 | 11 |
| Interest | 7 | 8 | 7 | 2 | 2 | 2 | 4 | 3 | 5 | 7 | 6 | 7 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 6 | 8 | 9 | 11 | 13 | 14 | 18 | 22 | 23 |
| Profit before tax | -12 | -5 | 17 | 18 | 39 | 29 | 33 | 12 | 41 | 110 | 164 | 206 | 208 |
| Tax % | -31% | -35% | 38% | 30% | 36% | 35% | 26% | 55% | 26% | 26% | 25% | 26% | |
| Net Profit | -8 | -3 | 11 | 12 | 25 | 19 | 25 | 5 | 31 | 81 | 123 | 153 | 154 |
| EPS in Rs | -6.95 | -2.49 | 8.93 | 10.24 | 20.35 | 15.74 | 20.33 | 4.39 | 25.29 | 67.22 | 101.17 | 126.22 | 126.83 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 10% | -0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 62.50% | 466.67% | 9.09% | 108.33% | -24.00% | 31.58% | -80.00% | 520.00% | 161.29% | 51.85% | 24.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | 404.17% | -457.58% | 99.24% | -132.33% | 55.58% | -111.58% | 600.00% | -358.71% | -109.44% | -27.46% |
Kingfa Science & Technology (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 48% |
| 5 Years: | 44% |
| 3 Years: | 48% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 32% |
| 5 Years: | 56% |
| 3 Years: | 51% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 18% |
| 3 Years: | 22% |
| Last Year: | 23% |
Last Updated: September 5, 2025, 9:05 am
Balance Sheet
Last Updated: June 16, 2025, 11:50 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 10 | 10 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 5 | 2 | 109 | 234 | 293 | 312 | 336 | 342 | 372 | 454 | 576 | 716 |
| Borrowings | 62 | 75 | 16 | 42 | 21 | 17 | 46 | 71 | 46 | 42 | 33 | 43 |
| Other Liabilities | 31 | 41 | 95 | 119 | 159 | 210 | 202 | 246 | 449 | 502 | 373 | 384 |
| Total Liabilities | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 |
| Fixed Assets | 24 | 25 | 29 | 76 | 88 | 85 | 107 | 129 | 126 | 123 | 252 | 244 |
| CWIP | 0 | 1 | 41 | 10 | 2 | 79 | 115 | 123 | 127 | 131 | 2 | 41 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 81 | 99 | 160 | 319 | 395 | 388 | 375 | 419 | 627 | 756 | 740 | 871 |
| Total Assets | 105 | 125 | 230 | 405 | 485 | 551 | 596 | 671 | 880 | 1,010 | 994 | 1,156 |
Below is a detailed analysis of the balance sheet data for Kingfa Science & Technology (India) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 12.00 Cr..
- For Reserves, as of Mar 2025, the value is 716.00 Cr.. The value appears strong and on an upward trend. It has increased from 576.00 Cr. (Mar 2024) to 716.00 Cr., marking an increase of 140.00 Cr..
- For Borrowings, as of Mar 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 33.00 Cr. (Mar 2024) to 43.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 384.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 373.00 Cr. (Mar 2024) to 384.00 Cr., marking an increase of 11.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,156.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 244.00 Cr.. The value appears to be declining and may need further review. It has decreased from 252.00 Cr. (Mar 2024) to 244.00 Cr., marking a decrease of 8.00 Cr..
- For CWIP, as of Mar 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 41.00 Cr., marking an increase of 39.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 871.00 Cr.. The value appears strong and on an upward trend. It has increased from 740.00 Cr. (Mar 2024) to 871.00 Cr., marking an increase of 131.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,156.00 Cr.. The value appears strong and on an upward trend. It has increased from 994.00 Cr. (Mar 2024) to 1,156.00 Cr., marking an increase of 162.00 Cr..
Notably, the Reserves (716.00 Cr.) exceed the Borrowings (43.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.00 | -69.00 | 11.00 | -23.00 | 20.00 | 18.00 | -3.00 | -51.00 | 36.00 | 86.00 | 152.00 | 182.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97 | 93 | 99 | 111 | 110 | 109 | 97 | 123 | 99 | 93 | 99 | 93 |
| Inventory Days | 54 | 64 | 85 | 69 | 85 | 63 | 67 | 100 | 110 | 94 | 76 | 82 |
| Days Payable | 66 | 72 | 127 | 108 | 108 | 119 | 115 | 152 | 181 | 155 | 110 | 94 |
| Cash Conversion Cycle | 85 | 85 | 57 | 72 | 86 | 53 | 49 | 71 | 28 | 32 | 66 | 80 |
| Working Capital Days | -7 | -14 | 66 | 59 | 96 | 59 | 55 | 57 | 39 | 45 | 78 | 85 |
| ROCE % | -9% | 4% | 22% | 9% | 13% | 9% | 10% | 4% | 16% | 25% | 30% | 31% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Diluted EPS (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| Cash EPS (Rs.) | 144.15 | 116.35 | 78.90 | 36.00 | 13.31 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 601.63 | 486.00 | 384.78 | 317.57 | 292.29 |
| Dividend / Share (Rs.) | 0.00 | 10.00 | 0.00 | 0.00 | 0.00 |
| Revenue From Operations / Share (Rs.) | 1440.64 | 1228.45 | 1159.08 | 865.13 | 517.93 |
| PBDIT / Share (Rs.) | 193.59 | 155.39 | 107.56 | 68.41 | 21.43 |
| PBIT / Share (Rs.) | 175.66 | 140.21 | 95.89 | 57.70 | 12.52 |
| PBT / Share (Rs.) | 170.16 | 135.58 | 90.49 | 34.14 | 9.79 |
| Net Profit / Share (Rs.) | 126.22 | 101.17 | 67.22 | 25.29 | 4.39 |
| PBDIT Margin (%) | 13.43 | 12.64 | 9.27 | 7.90 | 4.13 |
| PBIT Margin (%) | 12.19 | 11.41 | 8.27 | 6.66 | 2.41 |
| PBT Margin (%) | 11.81 | 11.03 | 7.80 | 3.94 | 1.88 |
| Net Profit Margin (%) | 8.76 | 8.23 | 5.79 | 2.92 | 0.84 |
| Return on Networth / Equity (%) | 20.97 | 20.81 | 17.47 | 7.96 | 1.50 |
| Return on Capital Employeed (%) | 29.00 | 28.66 | 24.65 | 17.08 | 3.92 |
| Return On Assets (%) | 13.22 | 12.32 | 8.05 | 3.49 | 0.79 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 |
| Total Debt / Equity (X) | 0.05 | 0.05 | 0.08 | 0.10 | 0.11 |
| Asset Turnover Ratio (%) | 1.62 | 1.48 | 1.49 | 1.35 | 0.98 |
| Current Ratio (X) | 2.02 | 1.80 | 1.37 | 1.30 | 1.45 |
| Quick Ratio (X) | 1.31 | 1.20 | 0.83 | 0.74 | 0.94 |
| Inventory Turnover Ratio (X) | 4.58 | 4.11 | 3.84 | 4.47 | 4.03 |
| Interest Coverage Ratio (X) | 35.23 | 33.55 | 19.95 | 15.67 | 7.84 |
| Interest Coverage Ratio (Post Tax) (X) | 23.97 | 22.84 | 13.47 | 11.19 | 2.61 |
| Enterprise Value (Cr.) | 3600.92 | 2398.91 | 1621.01 | 1546.18 | 724.65 |
| EV / Net Operating Revenue (X) | 2.06 | 1.61 | 1.15 | 1.48 | 1.16 |
| EV / EBITDA (X) | 15.36 | 12.75 | 12.44 | 18.66 | 27.92 |
| MarketCap / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| Price / BV (X) | 4.92 | 4.03 | 3.45 | 3.99 | 2.00 |
| Price / Net Operating Revenue (X) | 2.06 | 1.60 | 1.14 | 1.46 | 1.13 |
| EarningsYield | 0.04 | 0.05 | 0.05 | 0.01 | 0.01 |
After reviewing the key financial ratios for Kingfa Science & Technology (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Diluted EPS (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For Cash EPS (Rs.), as of Mar 25, the value is 144.15. This value is within the healthy range. It has increased from 116.35 (Mar 24) to 144.15, marking an increase of 27.80.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 601.63. It has increased from 486.00 (Mar 24) to 601.63, marking an increase of 115.63.
- For Dividend / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. It has decreased from 10.00 (Mar 24) to 0.00, marking a decrease of 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,440.64. It has increased from 1,228.45 (Mar 24) to 1,440.64, marking an increase of 212.19.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 193.59. This value is within the healthy range. It has increased from 155.39 (Mar 24) to 193.59, marking an increase of 38.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 175.66. This value is within the healthy range. It has increased from 140.21 (Mar 24) to 175.66, marking an increase of 35.45.
- For PBT / Share (Rs.), as of Mar 25, the value is 170.16. This value is within the healthy range. It has increased from 135.58 (Mar 24) to 170.16, marking an increase of 34.58.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 126.22. This value is within the healthy range. It has increased from 101.17 (Mar 24) to 126.22, marking an increase of 25.05.
- For PBDIT Margin (%), as of Mar 25, the value is 13.43. This value is within the healthy range. It has increased from 12.64 (Mar 24) to 13.43, marking an increase of 0.79.
- For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 12.19, marking an increase of 0.78.
- For PBT Margin (%), as of Mar 25, the value is 11.81. This value is within the healthy range. It has increased from 11.03 (Mar 24) to 11.81, marking an increase of 0.78.
- For Net Profit Margin (%), as of Mar 25, the value is 8.76. This value is within the healthy range. It has increased from 8.23 (Mar 24) to 8.76, marking an increase of 0.53.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.97. This value is within the healthy range. It has increased from 20.81 (Mar 24) to 20.97, marking an increase of 0.16.
- For Return on Capital Employeed (%), as of Mar 25, the value is 29.00. This value is within the healthy range. It has increased from 28.66 (Mar 24) to 29.00, marking an increase of 0.34.
- For Return On Assets (%), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 12.32 (Mar 24) to 13.22, marking an increase of 0.90.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.05. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.62. It has increased from 1.48 (Mar 24) to 1.62, marking an increase of 0.14.
- For Current Ratio (X), as of Mar 25, the value is 2.02. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 2.02, marking an increase of 0.22.
- For Quick Ratio (X), as of Mar 25, the value is 1.31. This value is within the healthy range. It has increased from 1.20 (Mar 24) to 1.31, marking an increase of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.58. This value is within the healthy range. It has increased from 4.11 (Mar 24) to 4.58, marking an increase of 0.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.23. This value is within the healthy range. It has increased from 33.55 (Mar 24) to 35.23, marking an increase of 1.68.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.97. This value is within the healthy range. It has increased from 22.84 (Mar 24) to 23.97, marking an increase of 1.13.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,600.92. It has increased from 2,398.91 (Mar 24) to 3,600.92, marking an increase of 1,202.01.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 2.06, marking an increase of 0.45.
- For EV / EBITDA (X), as of Mar 25, the value is 15.36. This value exceeds the healthy maximum of 15. It has increased from 12.75 (Mar 24) to 15.36, marking an increase of 2.61.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For Price / BV (X), as of Mar 25, the value is 4.92. This value exceeds the healthy maximum of 3. It has increased from 4.03 (Mar 24) to 4.92, marking an increase of 0.89.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.06. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 2.06, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.04, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Kingfa Science & Technology (India) Ltd:
- Net Profit Margin: 8.76%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29% (Industry Average ROCE: 16.3%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.97% (Industry Average ROE: 12.17%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 40.8 (Industry average Stock P/E: 47.93)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.05
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.76%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Plastics - Plastic & Plastic Products | Dhun Building, 3rd Floor, Chennai (Madras) Tamil Nadu 600002 | cs@kingfaindia.com http://www.kingfaindia.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bo Jingen | Managing Director |
| Mr. Doraiswami Balaji | Executive Director |
| Mr. Sun Yajie | Executive Director |
| Ms. Nilima Ramrao Shinde | Ind. Non-Executive Director |
| Mr. S K Subramanyan | Ind. Non-Executive Director |
| Mr. Ramachandran Sudhinder | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Kingfa Science & Technology (India) Ltd?
Kingfa Science & Technology (India) Ltd's intrinsic value (as of 26 October 2025) is 4649.81 which is 0.60% higher the current market price of 4,622.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 6,264 Cr. market cap, FY2025-2026 high/low of 4,987/2,451, reserves of ₹716 Cr, and liabilities of 1,156 Cr.
What is the Market Cap of Kingfa Science & Technology (India) Ltd?
The Market Cap of Kingfa Science & Technology (India) Ltd is 6,264 Cr..
What is the current Stock Price of Kingfa Science & Technology (India) Ltd as on 26 October 2025?
The current stock price of Kingfa Science & Technology (India) Ltd as on 26 October 2025 is 4,622.
What is the High / Low of Kingfa Science & Technology (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Kingfa Science & Technology (India) Ltd stocks is 4,987/2,451.
What is the Stock P/E of Kingfa Science & Technology (India) Ltd?
The Stock P/E of Kingfa Science & Technology (India) Ltd is 40.8.
What is the Book Value of Kingfa Science & Technology (India) Ltd?
The Book Value of Kingfa Science & Technology (India) Ltd is 602.
What is the Dividend Yield of Kingfa Science & Technology (India) Ltd?
The Dividend Yield of Kingfa Science & Technology (India) Ltd is 0.00 %.
What is the ROCE of Kingfa Science & Technology (India) Ltd?
The ROCE of Kingfa Science & Technology (India) Ltd is 30.6 %.
What is the ROE of Kingfa Science & Technology (India) Ltd?
The ROE of Kingfa Science & Technology (India) Ltd is 23.2 %.
What is the Face Value of Kingfa Science & Technology (India) Ltd?
The Face Value of Kingfa Science & Technology (India) Ltd is 10.0.